2020
The human microbiome and genitourinary malignancies
Nicolaro M, Portal D, Shinder B, Patel H, Singer E. The human microbiome and genitourinary malignancies. Annals Of Translational Medicine 2020, 8: 1245. PMID: 33178777, PMCID: PMC7607065, DOI: 10.21037/atm-20-2976.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsImmune checkpoint inhibitorsTyrosine kinase inhibitorsGenitourinary malignanciesResponse to certain drugsCheckpoint inhibitorsPredictors of diseaseOncological outcomesEffects of antibioticsProstate cancerMicrobial signaturesUrological malignanciesEtiology of disease statesTreatment coursePrognostic indicatorBladder cancerSystemic inflammationHealthy patientsUrinary microbiomeKidney cancerKinase inhibitorsMalignancyGenitourinary diseasesHuman microbiomeTherapeutic targetCancer
2019
Metastatic Prostate Cancer to the Renal Pelvis and Proximal Ureter: A Case Report and Review of the Literature.
Munshi F, Shinder B, Sadimin E, Mayer T, Singer E. Metastatic Prostate Cancer to the Renal Pelvis and Proximal Ureter: A Case Report and Review of the Literature. Cancer Studies And Therapeutics 2019, 4 PMID: 32148662, PMCID: PMC7059776.Peer-Reviewed Case Reports and Technical NotesRenal pelvisProstate cancerProximal ureterSymptoms of obstructive uropathyHigh index of suspicionFive-year survival rateMetastatic work-upMetastatic prostate cancerProstate cancer metastasisIndex of suspicionRight renal pelvisUreteral metastasisAsymptomatic massObstructive symptomsProstatic adenocarcinomaObstructive uropathyEventual metastasisLymph nodesCase reportClinical trial protocolsHigh indexVisceral diseaseWork-upSurvival rateProstate
2018
Results of Phase 1 study on cytoreductive radical prostatectomy in men with newly diagnosed metastatic prostate cancer
Yuh B, Kwon Y, Shinder B, Singer E, Jang T, Kim S, Stein M, Mayer T, Ferrari A, Lee N, Parikh R, Ruel N, Kim W, Horie S, Byun S, Ahlering T, Kim I. Results of Phase 1 study on cytoreductive radical prostatectomy in men with newly diagnosed metastatic prostate cancer. Prostate International 2018, 7: 102-107. PMID: 31485434, PMCID: PMC6713798, DOI: 10.1016/j.prnil.2018.10.002.Peer-Reviewed Original ResearchMetastatic prostate cancerCytoreductive radical prostatectomyPhase 1 studyProstate-specific antigenRadical prostatectomyCytoreductive surgeryProstate cancerSpecific antigenDeath 5 monthsAcute tubular necrosisMajor perioperative complicationsOverall complication rateRapid disease progressionDay of surgerySubset of menPerioperative complicationsPrimary endpointTemporary dialysisComplication rateDisseminated diseaseTubular necrosisMajor complicationsMean ageClinical trialsDisease progression
2017
Predicting clinically significant prostate cancer based on pre-operative patient profile and serum biomarkers
Faiena I, Kim S, Farber N, Kwon Y, Shinder B, Patel N, Salmasi A, Jang T, Singer E, Kim W, Kim I. Predicting clinically significant prostate cancer based on pre-operative patient profile and serum biomarkers. Oncotarget 2017, 5: 109783-109790. PMID: 29312648, PMCID: PMC5752561, DOI: 10.18632/oncotarget.21297.Peer-Reviewed Original ResearchClinical Gleason scoreBody mass indexProstate-specific antigenSignificant prostate cancerProstate acid phosphatasePreoperative prostate-specific antigenGleason scoreProstate cancerSerum biomarkersProstate weightParathyroid hormoneTotal prostate-specific antigenBias-corrected areaMultiple preoperative factorsPreoperative factorsOncologic characteristicsPatient characteristicsProstatectomy databaseMass indexRisk stratificationClinical stageUnivariate analysisPatient profilesHormone profilesMultivariate analysisRisk of complications and urinary incontinence following cytoreductive prostatectomy: a multi-institutional study
Kim DK, Parihar JS, Kwon YS, Kim S, Shinder B, Lee N, Farber N, Ahlering T, Skarecky D, Yuh B, Ruel N, Kim WJ, Rha KH, Kim IY. Risk of complications and urinary incontinence following cytoreductive prostatectomy: a multi-institutional study. Asian Journal Of Andrology 2017, 20: 9-14. PMID: 28440262, PMCID: PMC5753561, DOI: 10.4103/1008-682x.196852.Peer-Reviewed Original ResearchConceptsMetastatic prostate cancerCytoreductive prostatectomyUrinary incontinenceProstate cancerBlood lossRadical prostatectomyCare androgen-deprivation therapyBenefit of cytoreductionUrinary incontinence rateAndrogen deprivation therapyMulti-institutional clinical trialsIncidence of complicationsMajor complication rateOnly independent predictorLonger operative timeRisk of complicationsTertiary surgical centerMulti-institutional studyDeprivation therapyBony metastasesIncontinence ratesPerioperative complicationsComplication rateCRP groupIndependent predictors